Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation
Clinical and Translational Medicine · 2023-06 · 13 (6)
DOI: 10.1002/ctm2.1300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 19.06.2023. Verfasst von Zhehao Shi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding, Ferroptosis. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Ferroptosis is an important iron‐dependent form of cell death in hepatocellular carcinoma (HCC). Sorafenib, a potent ferroptosis inducer, is used to treat advanced HCC but its efficacy is limited by the development of drug resistance.
Methods
The effects of DUXAP8 expression on HCC progression were evaluated by TCGA database, Kaplan‐Meier analysis, and in situ hybridization analysis. Sorafenib resistant HCC cell lines were modeled in vitro to study the regulation of DUXAP8 on ferroptosis in HCC induced by sorafenib. We used RNA pull‐down, immunofluorescence assays, acyl‐biotinyl exchange assay and mass spectrometry analysis to assess the molecular mechanism of ferroptosis regulation by DUXAP8. Syngeneic subcutaneous and orthotopic CDX models were used to assess whether DUXAP8 inhibition improves HCC in vivo.
Results
LncRNA DUXAP8, which is highly expressed in liver cancer and associated with poor prognosis, contributes to sorafenib resistance through suppression of ferroptosis. In vitro tests revealed that DUXAP8 reduced the sensitivity of HCC to sorafenib‐induced ferroptosis by acting on SLC7A11, a subunit of the amino acid antiporter system xc‐. DUXAP8 facilitates SLC7A11 palmitoylation and impedes its lysosomal degradation, thereby enhancing SLC7A11 action and suppressing ferroptosis. RNA pull‐down and immunofluorescence assays confirmed that DUXAP8 decreased membrane translocation and promoted sorting of de‐palmitoylated SLC7A11 to lysosomes by binding of DUXAP8 to SLC7A11. In addition, mass spectrometric analysis found that the Cys414 residue of SLC7A11 might be the predominant mutant site responsible for molecular masking of SLC7A11 lysosomal sorting. Further, the antitumor effect of DUXAP8 knockdown was verified in orthotopic and subcutaneous CDX models.
Conclusions
Our findings suggest that a novel translational strategy combining sorafenib with DUXAP8 silencing to overcome drug resistance may improve treatment efficacy in patients with advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Organ Transplantation, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Shandong, China.
- Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Shandong, China.
- Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
ORCID-Profile: Gang Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shi, Z., Li, Z., Jin, B., Ye, W., Wang, L., Zhang, S., Zheng, J., Lin, Z., Chen, B., Liu, F., Zhang, B., Ding, X., Yang, Z., Shan, Y., Yu, Z., Wang, Y., Chen, J., Chen, Q., Roberts, L. R., & Chen, G. (2023). Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation. Clinical and Translational Medicine, 13(6). https://doi.org/10.1002/ctm2.1300
Vancouver
Shi Z, Li Z, Jin B, Ye W, Wang L, Zhang S, et al. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation. Clinical and Translational Medicine. 2023;13(6). doi:10.1002/ctm2.1300
BibTeX
@article{Shi2023,
author = {Shi, Zhehao and Li, Zhiming and Jin, Bin and Ye, Wen and Wang, Luhui and Zhang, Sina and Zheng, Jiuyi and Lin, Zixia and Chen, Bo and Liu, Fangting and Zhang, Baofu and Ding, Xiwei and Yang, Zhen and Shan, Yunfeng and Yu, Zhengping and Wang, Yi and Chen, Jicai and Chen, Qiang and Roberts, Lewis R and Chen, Gang},
title = {Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {6},
doi = {10.1002/ctm2.1300}
}
EUVIMED